CorRen Medical Secures $1.3M Seed Funding to Revolutionize PAD Diagnosis with UltraSense ABI Testing

CorRen Medical Inc. is thrilled to announce the successful raising of $1,300,000 in its latest funding round, marking a significant milestone in the company’s journey to revolutionize PAD diagnosis and treatment. Known for developing cutting-edge diagnostic solutions, CorRen is dedicated to addressing the limitations of today's Peripheral Artery Disease (PAD) screening methods. With its flagship product, UltraSense, CorRen is set to transform the diagnostics landscape by providing an autonomous, hands-free Ankle Brachial Index (ABI) test that is both accurate and user-friendly. The new funds will play a pivotal role in furthering UltraSense’s development and expediting its journey from prototype to market-ready solution. This investment comes at a crucial time when current ABI testing methods face shortcomings such as complexity and time constraints, limiting their efficiency and ultimately affecting patient outcomes. With a worldwide market potential estimated at $1.6 billion, UltraSense is engineered to offer a reimbursable alternative that not only simplifies the clinical workflow but also enhances diagnostic accuracy. The additional capital will be strategically deployed to refine the technology, expand clinical trials, and ensure regulatory compliance—all while maintaining a keen eye on affordability and accessibility for healthcare providers. By bridging the gap between technological innovation and everyday clinical practice, CorRen aims to significantly reduce the burden of PAD, ultimately extending better care and improved quality of life to patients worldwide.